The existence of two types of proteasome, the constitutive proteasome and the immunoproteasome, may serve as another layer of protection against autoimmunity

Medical Hypotheses

Volumn 78, Issue 1, 2012, Pages 138-141

  Eleftheriadis, Theodoros ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CONSTITUTIVE PROTEASOME; IMMUNOPROTEASOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; CANCER CELL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL KILLING; CELL MATURATION; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INFECTION; PROTEIN DEGRADATION; THYMUS; TUMOR IMMUNITY; VIRUS INFECTION;

AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; MODELS, IMMUNOLOGICAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; THYMUS GLAND;

EID: 83155175088     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.10.010     Document Type: Article

References (54)

1. Medzhitov R., Janeway C.A. Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298-300.
2. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
3. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995.
4. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004, 199:9-26.
5. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat Rev Immunol 2010, 10:403-414.
6. Hammer G.E., Kanaseki T., Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity 2007, 26:397-406.
7. Groettrup M., Kirk C.J., Basler M. Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 2010, 10:73-78.
8. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem 2009, 78:477-513.
9. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
10. Macagno A., Gilliet M., Sallusto F., Lanzavecchia A., Nestle F.O., Groettrup M. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. Eur J Immunol 1999, 29:4037-4042.
11. Li J., Schuler-Thurner B., Schuler G., Huber C., Seliger B. Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation. Int Immunol 2001, 13:1515-1523.
12. Gaczynska M., Rock K.L., Goldberg A.L. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993, 365:264-267.
13. Driscoll J., Brown M.G., Finley D., Monaco J.J. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993, 365:262-264.
14. Kuckelkorn U., Frentzel S., Kraft R., Kostka S., Groettrup M., Kloetzel P.M. Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-gamma. Eur J Immunol 1995, 25:2605-2611.
15. Kloetzel P.M. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001, 2:179-187.
16. Klein L., Hinterberger M., Wirnsberger G., Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol 2009, 9:833-844.
17. Chen W., Norbury C.C., Cho Y., Yewdell J.W., Bennink J.R. Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med 2001, 193:1319-1326.
18. Nil A., Firat E., Sobek V., Eichmann K., Niedermann G. Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets. Eur J Immunol 2004, 34:2681-2689.
19. Osterloh P., Linkemann K., Tenzer S., Rammensee H.G., Radsak M.P., Busch D.H., et al. Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc Natl Acad Sci U S A 2006, 103:5042-5047.
20. Basler M., Moebius J., Elenich L., Groettrup M., Monaco J.J. An altered T cell repertoire in MECL-1-deficient mice. J Immunol 2006, 176:6665-6672.
21. Anderson A.C., Nicholson L.B., Legge K.L., Turchin V., Zaghouani H., Kuchroo V.K. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice. mechanisms of selection of the self-reactive repertoire. J Exp Med 2000, 191:761-770.
22. Bouneaud C., Kourilsky P., Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000, 13:829-840.
23. Yan J., Mamula M.J. Autoreactive T cells revealed in the normal repertoire: escape from negative selection and peripheral tolerance. J Immunol 2002, 168:3188-3194.
24. Eleftheriadis T., Voyatzi S., Antoniadi G., Kartsios C., Liakopoulos V., Paraskevopoulos P., et al. Major histocompatibility complex class I restricted T-cell autoreactivity in human peripheral blood mononuclear cells. Cell Immunol 2006, 240:62-67.
25. Murata S., Takahama Y., Tanaka K. Thymoproteasome: probable role in generating positively selecting peptides. Curr Opin Immunol 2008, 20:192-196.
26. Akiyama K., Yokota K., Kagawa S., Shimbara N., Tamura T., Akioka H., et al. CDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y. Science 1994, 265:1231-1234.
27. Boes B., Hengel H., Ruppert T., Multhaup G., Koszinowski U.H., Kloetzel P.M. Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med 1994, 179:901-909.
28. Hallermalm K., Seki K., Wei C., Castelli C., Rivoltini L., Kiessling R., et al. Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 2001, 98:1108-1115.
29. Singh S., Awasthi N., Egwuagu C.E., Wagner B.J. Immunoproteasome expression in a nonimmune tissue, the ocular lens. Arch Biochem Biophys 2002, 405:147-153.
30. Leblond J., Hubert-Buron A., Bole-Feysot C., Ducrotte P., Dechelotte P., Coeffier M. Regulation of proteolysis by cytokines in the human intestinal epithelial cell line HCT-8: role of IFNgamma. Biochimie 2006, 88:759-765.
31. Kotamraju S., Matalon S., Matsunaga T., Shang T., Hickman-Davis J.M., Kalyanaraman B. Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radic Biol Med 2006, 40:1034-1044.
32. Shin E.C., Seifert U., Kato T., Rice C.M., Feinstone S.M., Kloetzel P.M., et al. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest 2006, 116:3006-3014.
33. Khan S., van den Broek M., Schwarz K., de Giuli R., Diener P.A., Groettrup M. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol 2001, 167:6859-6868.
34. Barton L.F., Cruz M., Rangwala R., Deepe G.S., Monaco J.J. Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection. J Immunol 2002, 169:3046-3052.
35. Gileadi U., Moins-Teisserenc H.T., Correa I., Booth B.L., Dunbar P.R., Sewell A.K., et al. Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein. J Immunol 1999, 163:6045-6052.
36. van Hall T., Sijts A., Camps M., Offringa R., Melief C., Kloetzel P.M., et al. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J Exp Med 2000, 192:483-494.
37. Morel S., Levy F., Burlet-Schiltz O., Brasseur F., Probst-Kepper M., Peitrequin A.L., et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000, 12:107-117.
38. Toes R.E., Nussbaum A.K., Degermann S., Schirle M., Emmerich N.P., Kraft M., et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001, 194:1-12.
39. Van den Eynde B.J., Morel S. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 2001, 13:147-153.
40. Kesmir C., van Noort V., de Boer R.J., Hogeweg P. Bioinformatic analysis of functional differences between the immunoproteasome and the constitutive proteasome. Immunogenetics 2003, 55:437-449.
41. Chapiro J., Claverol S., Piette F., Ma W., Stroobant V., Guillaume B., et al. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J Immunol 2006, 176:1053-1061.
42. Robek M.D., Garcia M.L., Boyd B.S., Chisari F.V. Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J Virol 2007, 81:483-491.
43. Dannull J., Lesher D.T., Holzknecht R., Qi W., Hanna G., Seigler H., et al. Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood 2007, 110:4341-4350.
44. Dalet A., Stroobant V., Vigneron N., Van den Eynde B.J. Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome. Eur J Immunol 2011, 41:39-46.
45. Hutchinson S., Sims S., O'Hara G., Silk J., Gileadi U., Cerundolo V., et al. PLoS One 2011, 6:e14646.
46. Swann J.B., Smyth M.J. Immune surveillance of tumors. J Clin Invest 2007, 117:1137-1146.
47. Ma W., Vigneron N., Chapiro J., Stroobant V., Germeau C., Boon T., et al. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. Int J Cancer 2011.
48. Egerer T., Martinez-Gamboa L., Dankof A., Stuhlmuller B., Dorner T., Krenn V., et al. Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjogren's syndrome. Arthritis Rheum 2006, 54:1501-1508.
49. Kimura H.J., Chen C.Y., Tzou S.C., Rocchi R., Landek-Salgado M.A., Suzuki K., et al. PLoS One 2009, 4:e7857.
50. Mishto M., Bellavista E., Ligorio C., Textoris-Taube K., Santoro A., Giordano M., et al. PLoS One 2010, 5:e9287.
51. Muchamuel T., Basler M., Aujay M.A., Suzuki E., Kalim K.W., Lauer C., et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009, 15:781-787.
52. Basler M., Dajee M., Moll C., Groettrup M., Kirk C.J. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010, 185:634-641.
53. Fujinami R.S., von Herrath M.G., Christen U., Whitton J.L. Molecular mimicry, bystander activation, or viral persistence. infections and autoimmune disease. Clin Microbiol Rev 2006, 19:80-94.
54. Rose N.R. Autoimmunity, infection and adjuvants. Lupus 2010, 19:354-358.